Cargando…
Descriptive analysis of postmarket surveillance data for hip implants
PURPOSE: Recent safety issues involving medical devices have highlighted the need for better postmarket surveillance (PMS) evaluation. This article aims to describe and to assess the quality of the PMS data for a medical device and, finally, to provide recommendations to improve the data gathering p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216945/ https://www.ncbi.nlm.nih.gov/pubmed/32128913 http://dx.doi.org/10.1002/pds.4971 |
_version_ | 1783532515267444736 |
---|---|
author | Pane, Josep Verhamme, Katia M. C. Rebollo, Irene Sturkenboom, Miriam C. J. M. |
author_facet | Pane, Josep Verhamme, Katia M. C. Rebollo, Irene Sturkenboom, Miriam C. J. M. |
author_sort | Pane, Josep |
collection | PubMed |
description | PURPOSE: Recent safety issues involving medical devices have highlighted the need for better postmarket surveillance (PMS) evaluation. This article aims to describe and to assess the quality of the PMS data for a medical device and, finally, to provide recommendations to improve the data gathering process. METHODS: A descriptive analysis of medical device reports (MDRs) on the use of MRA, a specific type of hip implant replacement submitted to the Food and Drug Administration Manufacturer and User Facility Device Experience database from 1 January 2008 to 31 December 2017. The number of reports was described as the number of MDRs per unique MDR number and stratified by different variables. The quality was assessed by the level of completeness of the collected PMS data. RESULTS: The total number of reports related to MRA was 2377, and the number of MDRs per year ranged between 84 in 2009 and 452 in 2017. Most of the reports were reported by manufacturer Depuy Johnson & Johnson and were reported by a physician. In 44.9% of the reports, the device problem was reported as “Unknown.” When the device problem was known, in the majority of cases, it was related to an implant fracture. The quality of the collected data was assessed as low due to missing information. CONCLUSION: The underlying data should meet high quality standards to generate more evidence and to ensure a timely signal generation. This case study shows that the completeness and quality of the MDRs can be improved. The authors propose the development of tools to ensure a more dynamic complaint data collection to contribute to this enhancement. |
format | Online Article Text |
id | pubmed-7216945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72169452020-05-13 Descriptive analysis of postmarket surveillance data for hip implants Pane, Josep Verhamme, Katia M. C. Rebollo, Irene Sturkenboom, Miriam C. J. M. Pharmacoepidemiol Drug Saf Original Reports PURPOSE: Recent safety issues involving medical devices have highlighted the need for better postmarket surveillance (PMS) evaluation. This article aims to describe and to assess the quality of the PMS data for a medical device and, finally, to provide recommendations to improve the data gathering process. METHODS: A descriptive analysis of medical device reports (MDRs) on the use of MRA, a specific type of hip implant replacement submitted to the Food and Drug Administration Manufacturer and User Facility Device Experience database from 1 January 2008 to 31 December 2017. The number of reports was described as the number of MDRs per unique MDR number and stratified by different variables. The quality was assessed by the level of completeness of the collected PMS data. RESULTS: The total number of reports related to MRA was 2377, and the number of MDRs per year ranged between 84 in 2009 and 452 in 2017. Most of the reports were reported by manufacturer Depuy Johnson & Johnson and were reported by a physician. In 44.9% of the reports, the device problem was reported as “Unknown.” When the device problem was known, in the majority of cases, it was related to an implant fracture. The quality of the collected data was assessed as low due to missing information. CONCLUSION: The underlying data should meet high quality standards to generate more evidence and to ensure a timely signal generation. This case study shows that the completeness and quality of the MDRs can be improved. The authors propose the development of tools to ensure a more dynamic complaint data collection to contribute to this enhancement. John Wiley & Sons, Inc. 2020-03-03 2020-04 /pmc/articles/PMC7216945/ /pubmed/32128913 http://dx.doi.org/10.1002/pds.4971 Text en © 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Reports Pane, Josep Verhamme, Katia M. C. Rebollo, Irene Sturkenboom, Miriam C. J. M. Descriptive analysis of postmarket surveillance data for hip implants |
title | Descriptive analysis of postmarket surveillance data for hip implants |
title_full | Descriptive analysis of postmarket surveillance data for hip implants |
title_fullStr | Descriptive analysis of postmarket surveillance data for hip implants |
title_full_unstemmed | Descriptive analysis of postmarket surveillance data for hip implants |
title_short | Descriptive analysis of postmarket surveillance data for hip implants |
title_sort | descriptive analysis of postmarket surveillance data for hip implants |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216945/ https://www.ncbi.nlm.nih.gov/pubmed/32128913 http://dx.doi.org/10.1002/pds.4971 |
work_keys_str_mv | AT panejosep descriptiveanalysisofpostmarketsurveillancedataforhipimplants AT verhammekatiamc descriptiveanalysisofpostmarketsurveillancedataforhipimplants AT rebolloirene descriptiveanalysisofpostmarketsurveillancedataforhipimplants AT sturkenboommiriamcjm descriptiveanalysisofpostmarketsurveillancedataforhipimplants |